Preliminary clinical study on the effect of metformin on prognosis of patients with oral squamous cell carcinoma after surgical treatment

doi:10.19439/j.sjos.2021.01.012

Abstract

Abstract: PURPOSE: To investigate the effect of metformin on the prognosis of patients with oral squamous cell carcinoma after surgical treatment. METHODS: Three hundred and forty-six patients with oral squamous cell carcinoma after operation in Xiangya Hospital of Central South University from October 2015 to October 2016 were selected and divided into experimental group and control group. In the experimental group, 71 patients with oral squamous cell carcinoma received metformin after surgery. The control group included 275 patients without metformin after surgery of oral squamous cell carcinoma. The clinical follow-up results of patients in the two groups were compared. SPSS 21.0 software package was used to analyze the data. RESULTS: Compared with the control group, the recurrent rate of the experimental group was lower. The difference was more significant in male patients, patients with primary tongue tumor, patients with highly differentiated squamous cell carcinoma, patients with cervical lymph node metastasis, and patients with a history of chewing areca nut (P<0.05). CONCLUSIONS: Metformin can decrease postoperative recurrent rate and metastatic rate of oral squamous cell carcinoma after surgery.

Key words: Oral squamous cell carcinoma, Recurrence, Metastasis, Metformin

CLC Number:

R739.8

HUANG Dan-ni, CHEN Wen-xin, XIONG Hao-feng, HU Xin, MAO Ting, SU Tong. Preliminary clinical study on the effect of metformin on prognosis of patients with oral squamous cell carcinoma after surgical treatment[J]. Shanghai Journal of Stomatology, 2021, 30(1): 61-65.

References

[1] Fu JY, Gao J, Zhang ZY, et al.Tea consumption and the risk of oral cancer incidence: a case-control study from China[J]. Oral Oncol, 2013, 49(9): 918-922.
[2] Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas[J]. Nature, 2015, 517(7536): 576-582.
[3] Chlebowski RT, Mctiernan A, Wactawski-Wende J, et al.Diabetes, metformin, and breast cancer in postmenopausal women[J]. J Clin Oncol, 2012, 30(23): 2844-2852.
[4] Kasper JS, Giovannucci E.A meta-analysis of diabetes mellitus and the risk of prostate cancer[J]. Cancer Epidemiol Biomarkers Prev, 2006, 15(11): 2056-2062.
[5] Garrett CR, Hassabo HM, Bhadkamkar NA, et al.Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer[J]. Br J Cancer, 2012, 106(8): 1374-1378.
[6] Mayer MJ, Klotz LH, Venkateswaran V.Metformin and prostate cancer stem cells: a novel therapeutic target[J]. Prostate Cancer Prostatic Dis, 2015, 18(4): 303-309.
[7] Lin H, Ying Y, Wang YY, et al.AMPK downregulates ALK2 via increasing the interaction between Smurf1 and Smad6, leading to inhibition of osteogenic differentiation[J]. Biochim Biophys Acta Mol Cell Res, 2017, 1864(12): 2369-2377.
[8] Tong D, Liu Q, Liu G, et al.Metformin inhibits castration-induced EMT in prostate cancer by repressing COX2/PGE2/STAT3 axis[J]. Cancer Lett, 2017, 389(1): 23-32.
[9] Cuyàs E, Fernández-Arroyo S, Buxó M, et al.Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients[J]. Aging (Albany NY), 2019, 11(9): 2874-2888.
[10] 林璐, 韩影, 熊浩峰, 等. 口腔鳞状细胞癌复发的临床和病理因素分析[J]. 北京医学, 2018, 40(10): 949-953.
[11] Bono F, De Smet F, Herbert C, et al.Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties[J]. Cancer Cell, 2013, 23(4): 477-488.
[12] Chen DS, Mellman I.Elements of cancer immunity and the cancer-immune set point[J]. Nature, 2017, 541(7637): 321-330.
[13] Quinn BJ, Kitagawa H, Memmott RM, et al.Repositioning metformin for cancer prevention and treatment[J]. Trends Endocrinol Metab, 2013, 24(9): 469-480.
[14] Tseng CH.Metformin may reduce oral cancer risk in patients with type 2 diabetes[J]. Oncotarget, 2016, 7(2): 2000-2008.
[15] Evans JM, Donnelly LA, Emslie-Smith AM, et al.Metformin and reduced risk of cancer in diabetic patients[J]. BMJ, 2005, 330(7503): 1304-1305.
[16] Bowker SL, Majumdar SR, Veugelers P, et al.Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin[J]. Diabetes Care, 2006, 29(2): 254-258.
[17] Jung Ys, Park CH, Eun CS, et al.Metformin use and the risk of colorectal adenoma: A systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2017, 32(5): 957-965.
[18] Mamtani R, Pfanzelter N, Haynes K, et al.Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas[J]. Diabetes Care, 2014, 37(7): 1910-1917.
[19] Bonanni B, Puntoni M, Cazzaniga M, et al.Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial[J]. J Clin Oncol, 2012, 30(21): 2593-2600.
[20] Sivalingam VN, Kitson S, Mcvey R, et al.Measuring the biological effect of presurgical metformin treatment in endometrial cancer[J]. Br J Cancer, 2016, 114(3): 281-289.
[21] Joshua AM, Zannella VE, Downes MR, et al.A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer[J]. Prostate Cancer Prostatic Dis, 2014, 17(3): 252-258.
[22] Curry J, Johnson J, Tassone P.Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial[J]. Laryngoscope, 2017, 127(8): 1808-1815.
[23] 郭峰, 翦新春, 周晌辉, 等. 口腔黏膜下纤维性变癌变的病理及临床生物学行为回顾性研究[J]. 中华口腔医学杂志, 2011, 46(8): 494-497.
[24] 母义明, 纪立农, 宁光, 等. 二甲双胍临床应用专家共识(2016年版)[J]. 中国糖尿病杂志, 2016, 24(10): 871-884.